Phase 2 QUADRA shows benefit extends to HRD-positive platinum-sensitive disease.
ONCOLOGY
Fully funded by 
Content independently selected
-
Niraparib shows activity in heavily pretreated ovarian cancer -
The study was carried out by the Cancer Research UK Institute at the University of Manchester.
-
LION: lymphadenectomy fails to up OS in advanced ovarian cancer Higher complications were reported after complete macroscopic resection.
-
Relapsed ovarian cancer: cediranib/olaparib combo extends PFS Phase 2 data show effect is driven by subset without a known BRCA mutation.
-
The novel Radiomic Prognostic Vector has been developed by researchers at Imperial College London and the University of Melbourne.
-
USPSTF: draft supports screening for BRCA risk in primary care A positive screen warrants genetic counseling and potential genetic testing.
-
Heavily treated ovarian cancer: avelumab does well in phase 1b JAVELIN Responses were irrespective of PD-L1 and BRCA status.
-
Ovarian cysts: observation a safe alternative to surgery in IOTA5 20% of masses resolve spontaneously within 2 years.
-
Results from the International Ovarian Tumor Analysis Phase 5 (IOTA5) study, the largest of its kind to date.
-
Breastfeeding may protect against ovarian cancer for 30+ years Breastfeeding for as little as 3 months shows protective effect.
-
Ovarian cancer: niraparib similarly effective in elderly patients Post hoc analysis showed similar PFS benefit regardless of age, BRCA mutation.
-
Randomised study of olaratumab plus liposomal doxorubicin in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
-
Recurrent ovarian cancer: cabozantinib fails phase 2 trial OS and toxicities were worse vs weekly paclitaxel.
-
Expert Commentary – Ovarian cancer: main improvements in 2018 PARP inhibitors in recurrent ovarian cancer increase PFS. But if used more and more as first-line therapy, what will we do with PARP inhibitors in later lines?